March 31, 2021

Via E-mail: AGO.highcostprescriptiondrugs@vermont.gov

Re: New Drug Introduction Report Pursuant to 18 V.S.A. 4637(c) To Whom It May Concern:

On March 4, 2021, pursuant to 18 V.S.A. § 4637(b), G1, Inc. (G1) submitted a new drug introduction notice for the following product:

NDC	Product Description
73462-0101-01	COSELA (trilaciclib) for injection, 300mg

G1 now provides the additional information pursuant to 18 V.S.A. § 4637(c). Per the requirements, we have limited the information we are reporting here to that which is otherwise publicly available or in the public domain.

1. **US and international marketing and pricing plans used at launch**:
    a. In February 2021, the U.S. Food and Drug Administration (FDA) approved COSELA (trilaciclib) to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer (ES-SCLC). The commercial launch of COSELA is being supported by our sales collaboration with Boehringer Ingelheim. G1 Therapeutics is managing all marketing, market access and clinical nurse educator functions, as well as product distribution. The G1 to One program will serve as a patient hub and provide patient and healthcare provider services. COSELA is due to be commercially available in the coming weeks.
2. **Estimated volume of patients:**
    a. 21,000 per year. Estimate based on ~29,000 1L-3L treated SCLC patients, with ~90% eligible in 1L, ~50% eligible in 2L and ~25% eligible in 3L – eligibility is based on estimated patients in each line who are prescribed etoposide/platinum or topotecan-containing regimens in line with our label
3. **Whether the FDA granted breakthrough therapy designation or priority review:**
    a. The product received both breakthrough therapy designation and priority review.
4. **Date and price of acquisition:**
    a. Not applicable. G1 developed the product.

Thank you for your consideration,

Anne-Marie Santoro
Director, Compliance
G1 Therapeutics, Inc.